Gilead Sciences News

Gilead Sciences is a multi-billion dollar biopharmaceutical company that develops medicines for a range of diseases. It is research based, so to stay up-to-date with that research, and to keep track of the performance of the company along with other issues, sign up for the Wiser Gilead Sciences news email. The drugs that Gilead Services produces treat conditions like HIV/AIDS, liver disease, cancer, cardiovascular and respiratory conditions. The company was founded in 1987 and is based in California. The president and chief executive officer is John Martin. It has about 7,000 employees and is ranked as one of the top drug companies in the US with sales in 2013 of over $11 billion. Its hepatitis-C drug, Sovaldi, is predicted to sell well, plus it is expected to continue its expansion through acquisitions. This is in addition to new drugs that the company is developing. The Gilead Sciences news email from Wiser is the best way to get the latest news and information on the company. It is free, so register today.

Recent Gilead Sciences News Coverage
 
Your Weekly Recommendations Tuesday, November 21, 2017
 
Recommended for you
Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea
PLOS Neglected Tropical Diseases • The French Cutaneous Leishmaniasis Study Group, The Leishman Network
Cytodyn Is Worth A Look Before Phase 3 HIV Data
Seeking Alpha • Terry Chrisomalis
Gilead Sciences: Tapping Into The Vast China Market For Growth
Seeking Alpha • Tran Biosci
Better Buy: Biogen Inc. vs. Gilead Sciences
nasdaq.com • Motley Fool
Your Daily Pharma Scoop: Gilead CAR-T Potential, Egalet Surges, Aerie Launches Mid-Stage Study
Seeking Alpha • Avisol Capital Partners
Internal logic
Week in Review • Karen Tkach Tuzman
Integrated BioSci Research On Atara Biotherapeutics: What's Next After CAR-T?
Seeking Alpha • Tran Biosci
How To Make Money With Gilead?
Seeking Alpha • Tran Biosci
North County School News, Nov. 16
San Diego Union Tribune • Laura Groch
3 Indisputable Reasons Why AbbVie Is the Best Big Pharma Stock
nasdaq.com • Motley Fool
 
Recommended for You
Epidemiology, Gilead Sciences
Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea
PLOS Neglected Tropical DiseasesThe French Cutaneous Leishmaniasis Study Group, The Leishman Network
Discussion In this cohort of unselected travellers with TL, L-AmB was associated with a suboptimal clinical benefit. Following conventional criteria for healing (excluding patients with improvement before day 90 and no subsequent follow-up), only 19 of 41 patients (46%) were cured 90...
Share
Gilead Sciences, Health Finance
Cytodyn Is Worth A Look Before Phase 3 HIV Data
Seeking AlphaTerry Chrisomalis
Summary Upcoming phase 3 combination data of Pro-140 with optimized background therapy could change the landscape of HIV treatment. Pro-140 has shown to be safe with fewer side effects, and has shown to suppress viral load in a lot of patients for...
Share
Gilead Sciences, Health Finance
Gilead Sciences: Tapping Into The Vast China Market For Growth
Seeking AlphaTran Biosci
Summary The upcoming launch of the hepatitis franchise in China is highly likely to ramp up sales. China has a huge population (so the overall sales will be robust). Stellar efficacy and safety of Sovaldi will enable the said drug to gain...
Share
Gilead Sciences
Better Buy: Biogen Inc. vs. Gilead Sciences
nasdaq.comMotley Fool
Historically, Biogen (NASDAQ: BIIB) has definitely been a better stock than Gilead Sciences (NASDAQ: GILD) . Whether you look at the last three, five, 10, 25 years, or even so far in 2017, Biogen has outperformed Gilead. But for investors, the future...
Share
Gilead Sciences, Health Finance
Your Daily Pharma Scoop: Gilead CAR-T Potential, Egalet Surges, Aerie Launches Mid-Stage Study
Seeking AlphaAvisol Capital Partners
Summary Gilead has adopted the right strategy in CAR-T. Egalet soars almost 40%. Aerie launches mid-stage study. This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Marketplace. Analysis of...
Share
Cancer, Gilead Sciences
Internal logic
Week in ReviewKaren Tkach Tuzman
Instead of designing T cells to fight cancer, an MIT group is using synthetic biology to directly manipulate the tumor cells and make them more immunogenic. The big advantage, says the team, is that the system uses intracellular cues to trigger tumor-specific...
Share
Cancer, Epidemiology
Integrated BioSci Research On Atara Biotherapeutics: What's Next After CAR-T?
Seeking AlphaTran Biosci
Summary The approval of Yescarta proved that CAR-T (based on CD4 T cells) works. Atara uses a similar mechanism of action and targets the CAR-T (that leverages on CD8). Data for ATA-129 for EBV franchise is robust. Phase 1 results for the...
Share
Cancer, Finance
How To Make Money With Gilead?
Seeking AlphaTran Biosci
Summary Growth of the Hepatitis franchises seem to be at the end of its robust cycle, but tapping into the vast China market may spark further growth. Share price has been on a downtrend (which creates an opportunistic purchase for the intelligent...
Share
Colleges & Universities, Education
North County School News, Nov. 16
San Diego Union TribuneLaura Groch
CARLSBAD Pacific Ridge supply drive aids Puerto Rico Pacific Ridge students recently collected and shipped nearly eight tons of supplies to hurricane-stricken Puerto Rico. The supply drive was held with biopharmaceutical company Gilead Sciences, and more than 10,000 items were collected in...
Share
Finance, Gilead Sciences
3 Indisputable Reasons Why AbbVie Is the Best Big Pharma Stock
nasdaq.comMotley Fool
What's the best big pharma stock? Of course, "best" can mean different things to different people. But with stocks, there are key metrics that can be used to determine which are better than others. And if one stock clearly dominates in several...
Share